Stifel analysts initiated coverage on Cytokinetics shares (NASDAQ:CYTK), assigning a Buy rating and setting a price target of ...
Stifel initiated coverage of Cytokinetics (CYTK) with a Buy rating and $80 price target Cytokinetics “is an out-of-favor stock” following the ...
Stifel analysts, led by Brian Chin, reaffirmed their Hold rating on shares of FormFactor (NASDAQ:FORM), with a steady price ...
Stifel lowered the firm’s price target on Fastenal (FAST) to $82 from $86 and keeps a Hold rating on the shares. Despite the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback